{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:43:15Z","timestamp":1777876995245,"version":"3.51.4"},"reference-count":65,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Chronic inflammatory diseases (CIDs), including rheumatic diseases and other inflammatory conditions, often affect women of reproductive age. Tumor necrosis factor inhibitors (TNFi) are widely used to treat CID, but there is limited information on outcomes of TNFi-exposed pregnancies. We evaluated pregnancy outcomes from 1392 prospectively reported pregnancies exposed to certolizumab pegol (CZP), a PEGylated, Fc-free TNFi with no to minimal placental transfer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>CZP-exposed pregnancies in patients with CID from the UCB Pharmacovigilance global safety database were reviewed from the start of CZP clinical development (July 2001) to 1 November 2020. To limit bias, the analysis focused on prospectively reported cases with known pregnancy outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In total, 1392 prospective pregnancies with maternal CZP exposure and known pregnancy outcomes ( n\u2009=\u20091425) were reported; 1021 had at least first-trimester CZP exposure. Live birth was reported in 1259\/1425 (88.4%) of all prospective outcomes. There were 150\/1425 (10.5%) pregnancy losses before 20\u2009weeks (miscarriage\/induced abortion), 11\/1425 (0.8%) stillbirths, and 5\/1392 (0.4%) ectopic pregnancies. Congenital malformations were present in 30\/1259 (2.4%) live-born infants, of which 26 (2.1%) were considered major according to the Metropolitan Atlanta Congenital Defects Program criteria. There was no pattern of congenital malformations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and conclusion:<\/jats:title>\n                    <jats:p>No signal for adverse pregnancy outcomes or congenital malformations was observed in CZP-exposed pregnancies. Although the limitations of data collected through this methodology (including underreporting, missing information, and absence of a comparator group) should be considered, these data provide reassurance for women with CID who require CZP treatment during pregnancy, and their treating physicians.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1759720x221087650","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T06:41:42Z","timestamp":1650004902000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8579-3470","authenticated-orcid":false,"given":"Megan","family":"Clowse","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Duke University Medical Center, 3535, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Fischer-Betz","sequence":"additional","affiliation":[{"name":"Department for Rheumatology and Hiller Research Institute, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Nelson-Piercy","sequence":"additional","affiliation":[{"name":"Department of Women and Children\u2019s Health, Guy\u2019s and St Thomas\u2019 Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela E.","family":"Scheuerle","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Genetics and Metabolism, UT Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Stephan","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marla","family":"Dubinsky","sequence":"additional","affiliation":[{"name":"The Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kumke","sequence":"additional","affiliation":[{"name":"UCB Pharma, Monheim am Rhein, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachna","family":"Kasliwal","sequence":"additional","affiliation":[{"name":"UCB Pharma, Slough, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Lauwerys","sequence":"additional","affiliation":[{"name":"UCB Pharma, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frauke","family":"F\u00f6rger","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Inselspital, University Hospital and University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"bibr1-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22516"},{"key":"bibr2-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004081"},{"key":"bibr3-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1002\/art.30210"},{"key":"bibr4-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207992"},{"key":"bibr5-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24111"},{"key":"bibr6-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key053"},{"key":"bibr7-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.15836"},{"key":"bibr8-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2923"},{"key":"bibr9-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.271"},{"key":"bibr10-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15654"},{"key":"bibr11-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.13946"},{"key":"bibr12-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.5595"},{"key":"bibr13-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1506575"},{"key":"bibr14-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1002\/art.41191"},{"key":"bibr15-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez405"},{"key":"bibr16-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70359-2"},{"key":"bibr17-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4410"},{"key":"bibr18-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1556740"},{"key":"bibr19-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.12192"},{"key":"bibr20-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208840"},{"key":"bibr21-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev404"},{"key":"bibr22-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16915"},{"key":"bibr23-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221036"},{"key":"bibr24-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/j9ysbm"},{"key":"bibr25-1759720X221087650","unstructured":"European Medicines Agency. Cimzia summary of product characteristics, 2020, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cimzia-epar-product-information_en.pdf (accessed August 2021)."},{"key":"bibr26-1759720X221087650","unstructured":"US Food and Drug Administration (FDA). Label: CIMZIA (certolizumab pegol), 2019, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125160s237lbl.pdf (accessed August 2021)."},{"key":"bibr27-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00334-7"},{"key":"bibr28-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1002\/bdr2.1615"},{"key":"bibr29-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212196"},{"key":"bibr30-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.05.040"},{"key":"bibr31-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211384"},{"key":"bibr32-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140189"},{"key":"bibr33-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1002\/art.40508"},{"key":"bibr34-1759720X221087650","volume-title":"International statistical classification of diseases and related health problems","author":"World Health Organization (WHO)","year":"2004","edition":"2"},{"key":"bibr35-1759720X221087650","volume-title":"Born too soon, the global action report on preterm birth","author":"World Health Organization (WHO)","year":"2012"},{"key":"bibr36-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1002\/uog.19073"},{"issue":"2","key":"bibr37-1759720X221087650","volume":"79","author":"Metropolitan Atlanta Congenital Defects Program (MACDP)","year":"2007","journal-title":"Birth Defects Res"},{"key":"bibr38-1759720X221087650","unstructured":"European Surveillance of Congenital Anomalies (EUROCAT). EUROCAT guide 1.4: Instruction for the registration of congenital anomalies, 2013, https:\/\/eu-rd-platform.jrc.ec.europa.eu\/sites\/default\/files\/JRC-EUROCAT-Full-Guide-1-4-version-01-Dec-2020.pdf (accessed August 2021)."},{"key":"bibr39-1759720X221087650","volume":"363","author":"Langan SM","year":"2018","journal-title":"BMJ"},{"key":"bibr40-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.299.6698.541"},{"key":"bibr41-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(02)04694-0"},{"key":"bibr42-1759720X221087650","unstructured":"Eurostat. Abortion indicators, 2021, https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/demo_fabortind\/default\/table?lang=en (accessed August 2021)."},{"key":"bibr43-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.ss6907a1"},{"issue":"1","key":"bibr44-1759720X221087650","first-page":"1","volume":"57","author":"Centers for Disease Control Prevention (CDC)","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"bibr45-1759720X221087650","unstructured":"European Surveillance of Congenital Anomalies (EUROCAT). Prevalence charts and tables, 2021, https:\/\/eu-rd-platform.jrc.ec.europa.eu\/eurocat\/eurocat-data\/prevalence_en (accessed August 2021)."},{"issue":"1","key":"bibr46-1759720X221087650","first-page":"1","volume":"61","author":"Martin JA","year":"2012","journal-title":"Natl Vital Stat Rep"},{"issue":"7","key":"bibr47-1759720X221087650","first-page":"1","volume":"60","author":"Ventura SJ","year":"2012","journal-title":"Natl Vital Stat Rep"},{"key":"bibr48-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7251.1708"},{"key":"bibr49-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(01)00613-3"},{"key":"bibr50-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000001152"},{"key":"bibr51-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2015-207013"},{"key":"bibr52-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.11.038"},{"key":"bibr53-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223603"},{"key":"bibr54-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15956"},{"key":"bibr55-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15971"},{"key":"bibr56-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.501"},{"key":"bibr57-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1002\/art.40536"},{"key":"bibr58-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60074-4"},{"key":"bibr59-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3MR0615-272RR"},{"key":"bibr60-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002746"},{"key":"bibr61-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7281.266"},{"key":"bibr62-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2018.06.002"},{"key":"bibr63-1759720X221087650","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12653"},{"key":"bibr64-1759720X221087650","unstructured":"General Data Protection Regulation (EU GDPR) Article 9(2)(i), https:\/\/gdpr-text.com\/read\/article-9\/ (accessed January 2022)."},{"key":"bibr65-1759720X221087650","unstructured":"Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, https:\/\/aspe.hhs.gov\/report\/health-insurance-portability-and-accountability-act-1996 (accessed January 2022)."}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X221087650","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X221087650","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X221087650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:38:22Z","timestamp":1777588702000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X221087650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":65,"alternative-id":["10.1177\/1759720X221087650"],"URL":"https:\/\/doi.org\/10.1177\/1759720x221087650","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"1759720X221087650"}}